SCOLR, Inc. Presents Drug Delivery Research at Controlled Release Society Annual Meeting.

Business Editors/Health/Medical Writers

2004 CRS Annual Meeting

BELLEVUE, Wash.--(BUSINESS WIRE)--June 14, 2004

SCOLR, Inc. (Amex:DDD) announced today that it is presenting drug delivery research at the 2004 Controlled Release Society (CRS) Annual Meeting to be held June 12-16 in Honolulu, Hawaii (http://www.controlledrelease.org).

SCOLR will present Poster No. 373, "Methods for Dissolution Profile Determination of Probiotic Bacteria from Controlled Release Solid Oral Dosage Forms via Direct Enumeration Fluorochrome Staining," from 1:45 p.m. to 3:00 p.m. on Monday, June 14, 2004.

CRS is an international organization which serves 3,000 members from more than 50 countries comprised from the worlds of industry, academia and government. Its mission is to advance the science and technology of chemical and biological delivery systems. SCOLR welcomes the opportunity to engage the pharmaceutical scientific community with discussions of its patented, advanced oral drug delivery technologies. In addition, SCOLR will exhibit at the CRS show in booths #19 & #20.

Based in Bellevue, Wash., SCOLR, Inc. is a specialty pharmaceutical company leveraging formulation expertise and its patented CDT(R) platform to introduce distinctive and novel OTC products, prescription drugs and dietary supplements. SCOLR's CDT drug delivery platform provides distinctive products with tangible benefits for the consumer and competitive commercial advantages for licensees. For more information on SCOLR, please call 425-373-0171 or visit http://www.SCOLR.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to continue to successfully develop new formulations, initiate and complete successful human studies and clinical trials, obtain regulatory approval, to market and to provide its products and services and maintain their effectiveness, the continuation of arrangements with the Company's product development partners and customers, competition, government regulation, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties which are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.